Connect with us

Hi, what are you looking for?

POZ

UNAIDS to downsize PH office

UNAIDS is expected to cut its staff by over 50%, and shift most of them to more affordable locations like Bonn, Nairobi, and Johannesburg. A casualty: its office in Manila.

The Joint United Nations Programme on HIV and AIDS (UNAIDS) will be cutting its presence in the Philippines as part of the global downsizing of the United Nations (UN) agency. Post-downsizing, the UNAIDS Country Office (UCO) in the Philippines is projected to have only one staffer left.

The UNAIDS describes itself as the “main advocate for accelerated, comprehensive and coordinated global action on the HIV/AIDS pandemic”. It was established in 1996 to supplement HIV policy gaps not addressed by the World Health Organization (WHO).

Outrage Magazine has reached out to the UNAIDS country director, Dr. Louie R. Ocampo, but no statement has been released as of press time.

In a call for support for the retention of the UCO, a local non-government organization – Action for Health Initiatives, Inc. (ACHIEVE) – stated that this UCO “has played a vital role in guiding the national HIV response through its technical expertise, support for civil society, and commitment to rights-based, community-led approaches. Its continued presence is crucial as the country faces a growing HIV epidemic and significant funding gaps.”

Currently, 57 new HIV infections are reported per day in the Philippines, most of them involving Filipinos aged 15-35 years old. By end-2025, the number of people living with HIV in the country is estimated to reach 252,800.

UNAIDS is expected to cut its staff by over 50%, and shift most of them to more affordable locations like Bonn, Nairobi, and Johannesburg. At the end of the restructuring, UNAIDS is expected to only be present in 36 countries. In particular, staff number will be cut from around 600 currently to around 280-300.

Advertisement
Advertisement

Like Us On Facebook

YOU MAY ALSO LIKE

POZ

With the new pill, most participants experienced fewer lipid-related side effects, such as increased cholesterol levels, suggesting an additional potential benefit for those at risk of heart...

POZ

The medication, anifrolumab, blocks type 1 interferon and is used to treat systemic lupus erythematosus, SLE, an autoimmune disease.

POZ

Developing an intermittent treatment relieves the need for daily pills and, given that no medicine is needed at home, directly addresses the stigma that...

POZ

The probability of being employed declines by 4%, work hours decrease by 5%, and income declines by 9% after HIV diagnosis. HIV also leads...

Advertisement